Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botto, Alice Di Rocco, Maria Giuseppina Cabras, Maria Concetta Petti, Vittorio Stefoni, Alessandro Broccoli, Stefano Fanti, Cinzia Pellegrini, Gian Carlo Montini, Letizia Gandolfi, Enrico Derenzini, Lisa Argnani, Mariapaola Fina, Alessandra Tucci, Chiara Bottelli, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age ≥60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by 90Y-ibritumomab tiuxetan 6 to 10 weeks later. Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after 90Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. 90Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by 90Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.

Original languageEnglish
Pages (from-to)3998-4004
Number of pages7
JournalClinical Cancer Research
Volume16
Issue number15
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Radioimmunotherapy
Safety
ibritumomab tiuxetan
Platelet Transfusion
Feasibility Studies
Vincristine
Prednisone
Neutropenia
Thrombocytopenia
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Research Design
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. / Zinzani, Pier Luigi; Rossi, Giuseppe; Franceschetti, Silvia; Botto, Barbara; Di Rocco, Alice; Cabras, Maria Giuseppina; Petti, Maria Concetta; Stefoni, Vittorio; Broccoli, Alessandro; Fanti, Stefano; Pellegrini, Cinzia; Montini, Gian Carlo; Gandolfi, Letizia; Derenzini, Enrico; Argnani, Lisa; Fina, Mariapaola; Tucci, Alessandra; Bottelli, Chiara; Pileri, Stefano; Baccarani, Michele.

In: Clinical Cancer Research, Vol. 16, No. 15, 01.08.2010, p. 3998-4004.

Research output: Contribution to journalArticle

Zinzani, PL, Rossi, G, Franceschetti, S, Botto, B, Di Rocco, A, Cabras, MG, Petti, MC, Stefoni, V, Broccoli, A, Fanti, S, Pellegrini, C, Montini, GC, Gandolfi, L, Derenzini, E, Argnani, L, Fina, M, Tucci, A, Bottelli, C, Pileri, S & Baccarani, M 2010, 'Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients', Clinical Cancer Research, vol. 16, no. 15, pp. 3998-4004. https://doi.org/10.1158/1078-0432.CCR-10-0162
Zinzani, Pier Luigi ; Rossi, Giuseppe ; Franceschetti, Silvia ; Botto, Barbara ; Di Rocco, Alice ; Cabras, Maria Giuseppina ; Petti, Maria Concetta ; Stefoni, Vittorio ; Broccoli, Alessandro ; Fanti, Stefano ; Pellegrini, Cinzia ; Montini, Gian Carlo ; Gandolfi, Letizia ; Derenzini, Enrico ; Argnani, Lisa ; Fina, Mariapaola ; Tucci, Alessandra ; Bottelli, Chiara ; Pileri, Stefano ; Baccarani, Michele. / Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 15. pp. 3998-4004.
@article{e41fc0935f0048ff84b25d997c2eb7f1,
title = "Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients",
abstract = "Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age ≥60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by 90Y-ibritumomab tiuxetan 6 to 10 weeks later. Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80{\%}, including 73{\%} complete remissions and 7{\%} partial remissions. Eight (50{\%}) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after 90Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85{\%}, with a 2-year overall survival of 86{\%}. 90Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by 90Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.",
author = "Zinzani, {Pier Luigi} and Giuseppe Rossi and Silvia Franceschetti and Barbara Botto and {Di Rocco}, Alice and Cabras, {Maria Giuseppina} and Petti, {Maria Concetta} and Vittorio Stefoni and Alessandro Broccoli and Stefano Fanti and Cinzia Pellegrini and Montini, {Gian Carlo} and Letizia Gandolfi and Enrico Derenzini and Lisa Argnani and Mariapaola Fina and Alessandra Tucci and Chiara Bottelli and Stefano Pileri and Michele Baccarani",
year = "2010",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-10-0162",
language = "English",
volume = "16",
pages = "3998--4004",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

AU - Zinzani, Pier Luigi

AU - Rossi, Giuseppe

AU - Franceschetti, Silvia

AU - Botto, Barbara

AU - Di Rocco, Alice

AU - Cabras, Maria Giuseppina

AU - Petti, Maria Concetta

AU - Stefoni, Vittorio

AU - Broccoli, Alessandro

AU - Fanti, Stefano

AU - Pellegrini, Cinzia

AU - Montini, Gian Carlo

AU - Gandolfi, Letizia

AU - Derenzini, Enrico

AU - Argnani, Lisa

AU - Fina, Mariapaola

AU - Tucci, Alessandra

AU - Bottelli, Chiara

AU - Pileri, Stefano

AU - Baccarani, Michele

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age ≥60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by 90Y-ibritumomab tiuxetan 6 to 10 weeks later. Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after 90Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. 90Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by 90Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.

AB - Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age ≥60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by 90Y-ibritumomab tiuxetan 6 to 10 weeks later. Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after 90Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. 90Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by 90Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.

UR - http://www.scopus.com/inward/record.url?scp=77955119703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955119703&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0162

DO - 10.1158/1078-0432.CCR-10-0162

M3 - Article

C2 - 20542986

AN - SCOPUS:77955119703

VL - 16

SP - 3998

EP - 4004

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -